Patents Assigned to Compugen Ltd.
  • Novel nucleic acid and amino acid sequences
    Publication number: 20040219583
    Abstract: The invention concerns novel nucleic acid sequences, amino acid sequences coded thereby and method of detection using the above. The novel nucleic acid sequences are naturally occurring splice variants of a prostate specific antigen sequence (PSA) or of the KLK-2 gene.
    Type: Application
    Filed: March 16, 2004
    Publication date: November 4, 2004
    Applicant: Compugen Ltd.
    Inventors: Kinneret Savitzky, Liat Mintz, Anat David, Idit Azar
  • Variant of TNF-receptor
    Publication number: 20040170975
    Abstract: The invention concerns nucleic acid and amino acid sequences of variants of TNF-receptor obtained by alternative splicing. The invention also concerns expression vectors, host cells, pharmaceutical compositions, and detection assays making use of these sequences, as well as antibodies reactive with the sequences.
    Type: Application
    Filed: February 28, 2002
    Publication date: September 2, 2004
    Applicant: Compugen Ltd.
    Inventors: Kinneret Savitzky, Amir Toporik, Sharon Biton
  • VEGF nucleic acid and amino acid sequences
    Patent number: 6783954
    Abstract: The invention concerns novel nucleic acid sequences and amino acid sequences of a novel variant of vascular endothelial growth factor (VEGF). The invention further concerns expression vectors and host cells containing said sequences as well as pharmaceutical compositions and detection methods using said sequences.
    Type: Grant
    Filed: June 20, 2001
    Date of Patent: August 31, 2004
    Assignee: Compugen Ltd.
    Inventors: Liat Mintz, Kinneret Savitzky, Sharon Engel
  • Nucleic acid and amino acid sequences
    Patent number: 6740516
    Abstract: An isolated nucleic acid sequence depicted in SEQ ID NO:6 is an alternative splice variant of human kallikrien-2 gene (KLK-2). An expression vector containing the splice variant and a host cell transfected by the expression vector are provided. The nucleic acid is useful for determining the level of nucleic acid sequences of human kallikrien variants in a biological sample.
    Type: Grant
    Filed: January 8, 2001
    Date of Patent: May 25, 2004
    Assignee: Compugen Ltd.
    Inventors: Kinneret Savitzky, Liat Mintz, Anat David, Idit Azar
  • Alternative splice variants of CD40
    Patent number: 6720182
    Abstract: The invention concerns novel nucleic acid sequences and amino acid sequences obtained by alternative splicing, expression vectors, host cell and pharmaceutical compositions comprising said sequences.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: April 13, 2004
    Assignee: Compugen Ltd. Corporation
    Inventors: Kinneret Savitzky, Liat Mintz, Sharon Engel, Jeanne Bernstein
  • Method and apparatus for mRNA assembly
    Patent number: 6625545
    Abstract: A method of obtaining an mRNA sequence having alternative spliced variants from a database of ESTs, comprising: providing a raw database comprising a plurality of ESTs; and assembling ones of said ESTs into mRNA sequences, wherein said assembling includes identifying alternative spliced regions.
    Type: Grant
    Filed: August 13, 1998
    Date of Patent: September 23, 2003
    Assignee: Compugen Ltd.
    Inventors: Mor Amitai, Raveh Avraham Gill-More, Eran Halperin, Avner Magen, Sarah Rachel Pollock
  • Novel nucleic acid and amino acid sequences
    Publication number: 20030125295
    Abstract: The invention concerns novel nucleic acid sequences and amino acid sequences of a novel variant of vascular endothelial growth factor (VEGF). The invention further concerns expression vectors and host cells containing said sequences as well as pharmaceutical compositions and detection methods using said sequences.
    Type: Application
    Filed: November 19, 2002
    Publication date: July 3, 2003
    Applicant: Compugen Ltd.
    Inventors: Liat Mintz, Kinneret Savitzky, Sharon Engel
  • Variant of vascular endothelial growth factor
    Patent number: 6506884
    Abstract: The invention concerns novel nucleic acid sequences and amino acid sequences of a novel variant of vascular endothelial growth factor (VEGF). The invention further concerns expression vectors and host cells containing said sequences as well as pharmaceutical compositions and detection methods using said sequences.
    Type: Grant
    Filed: March 6, 2000
    Date of Patent: January 14, 2003
    Assignee: Compugen Ltd.
    Inventors: Liat Mintz, Kinneret Savitzky, Sharon Engel
  • Variants of protein kinases
    Publication number: 20020110811
    Abstract: The present invention concerns nucleic acid sequences and amino acid sequences of dominant negative variants of kinases, i.e. of sequences which inhibit activity of kinases in a dominant manner. The invention also concerns pharmaceutical compositions and detection methods using these sequences.
    Type: Application
    Filed: January 26, 2001
    Publication date: August 15, 2002
    Applicant: Compugen Ltd.
    Inventors: Zurit Levine, Jeanne Bernstein